ADC Therapeutics SA
2 known investors
ADC Therapeutics develops antibody-drug conjugate cancer therapies, with an FDA-approved product (ZYNLONTA®) for treating relapsed or refractory large B-cell lymphoma and other hematologic cancers. The company is expanding its pipeline to address unmet medical needs in hematologic and solid tumors.